|
Biogen Idec Given “Neutral” Rating at Piper Jaffray (BIIB)
Mideast Time … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
Daclizumab (Multiple Sclerosis) – Forecast and Market Analysis to 2022: New …
SBWire (press release) Boston, MA — (SBWIRE) — 07/03/2013 — GlobalData has released its new PharmaPoint Drug Evaluation report, “Daclizumab (Multiple Sclerosis) – Forecast and Market Analysis to 2022″. Multiple sclerosis (MS) is a chronic, inflammatory neurological … |
|
Multiple Sklerose: Ein Anti-CD25-Antikörper verringert die Schubrate
Deutsches Ärzteblatt Daclizumab ist ein humanisierter monoklonaler Antikörper, der an CD25-Rezeptoren antagonistisch wirkt und immunologische Prozesse beeinflusst, die bei der multiplen Sklerose (MS) eine Rolle spielen. Bei einer Modifikation des Antikörpers (DAC HYP) … |
|
Piper Jaffray Reiterates “Neutral” Rating for Biogen Idec (BIIB)
Watch List News (press release) … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
JIM – Un nouvel anticorps monoclonal pour le traitement de la sclérose en plaques
Journal International de Médecine (Inscription) Ainsi, le daclizumab est un anticorps monoclonal humanisé spécifique du récepteur CD25 diminuant l’activation immunitaire via l’interleukine 2. Plus de 600 patients ont été inclus dans l’étude SELECT, randomisée, en double aveugle et contre placebo … |
|
Stock Analysts’ Ratings Reiterations for July, 1st (AMP, BBRY, BIIB, COH, CRM …
Zolmax … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
Biogen Idec Stock Rating Reaffirmed by Piper Jaffray (BIIB)
Zolmax … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors
Benzinga … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
Update MS: Immunsystem, nerv’ nicht!
DocCheck News Ähnlich erfolgversprechend sind Arbeiten zu Daclizumab. Der humanisierte, monoklonale Antikörper blockiert Interleukin-2-Rezeptoren und supprimiert Immunreaktionen. Davon profitierten noch bis 2008 Patienten nach einer Nierentransplantation. |
|
Biogen Idec Inc. – Shareholder/Analyst Call
Seeking Alpha Daclizumab is an antibody, again, being developed for multiple sclerosis, together with our partner, AbbVie. We had one large Phase II trial for that, that read out last year that had quite positive data. There’s another Phase III trial that is fully … |